Now Available:
Download the podcast of Dr. Cohen's video presentation

With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.

MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.

Consumer News: Learn what your patients are reading in the popular press

Newer Rheumatoid Arthritis Drugs Lower Production of B Cells
New findings suggest that drugs such as Enbrel, Humira, and Remicade reduce activity of abnormal B-cells, benefiting the patient's immune system...

New from PubMed: Keep up-to-date with what is on PubMed

Association Between Psoriasis and the Metabolic Syndrome
Researchers have found a possible association between psoriasis and the metabolic syndrome, and have suggested possible new treatment options for the management of psoriasis...



MSK Video Report:
Current and Available Treatment Options
Dr. Marc Cohen looks at the current state of infusion therapy for the treatment of RA...

Bones: Do Calcium Supplements Help Bones at the Expense of the Heart?
Calcium supplements may increase the risk of heart attack and stroke in healthy postmenopausal women...

Bones: Low Serum Testosterone Predicts Fracture Risk in Older Men
Men with serum testosterone ‹294 ng/dL have a significantly increased risk of nontraumatic fracture and should be referred for bone density assessment...

Bones: Adding Vitamin D Reduces Risk of Falls in High-Risk Elderly Women
Community-dwelling elderly women with a history of falling and vitamin D deficiency have a 19% reduction in falls when supplementary vitamin D is added to calcium, even if they live in sunny areas...

BioPharm Business: Amgen Reports Denosumab Osteoporosis Study Met Primary and All Secondary BMD Endpoints in a Direct Comparison With Weekly Alendronate (Fosamax)
Amgen Inc announced findings from a head-to-head, double-blind study comparing the effects of twice-yearly subcutaneous injections of denosumab versus weekly oral doses of alendronate in postmenopausal women with low bone mineral density...

BioPharm Business: Genentech, Biogen Idec, Roche Report Rituxan (rituximab, MabThera) Phase III Trial Meets Study Endpoints in RA; Use as First-Line Biologic Therapy Improves Symptoms
Genentech, Inc, Biogen Idec, and Roche Pharmaceuticals announced that a pivotal phase III study of rituximab (Rituxan) met its primary endpoint of greater proportion of biologic-naïve RA patients achieving ACR20 response at week 24, compared with placebo...

BioPharm Business: Tolerx Achieves Milestone With Completion of Phase Ib Study of TRX1, a Humanized Nondepleting Anti-CD4 Monoclonal Antibody, in Cutaneous Lupus Erythematosus
Tolerx, Inc announced the successful completion of a phase Ib clinical study of TRX1, a humanized anti-CD4 monoclonal antibody, in subjects with refractory cutaneous lupus erythematosus...

To remove your e-mail address from our mailing list, please reply to this e-mail with "unsubscribe" in the subject line. For questions and comments regarding this newsletter please contact .